In eyes with CRVO, macular edema is the main cause of vision loss, and the use of intravitreal anti-VEGF therapy [11–14, 16] or dexamethasone implants [17, 18] has considerably improved the visual prognosis of patients with CRVO. The gene discussed is VEGFA; the disease is macular retinal edema.